(Q39029990)

8 September 2017

title

Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway (English)

1 reference

8 September 2017

1 reference

S Bunda

1

1 reference

8 September 2017

K Qin

2

1 reference

8 September 2017

K Kommaraju

3

1 reference

8 September 2017

P Heir

4

1 reference

8 September 2017

M Ohh

5

1 reference

8 September 2017

language of work or name

English

0 references

publication date

27 January 2014

1 reference

8 September 2017

1 reference

8 September 2017

volume

34

1 reference

8 September 2017

issue

6

1 reference

8 September 2017

page(s)

789-797

1 reference

Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Differential ubiquitin binding of the UBA domains from human c-Cbl and Cbl-b: NMR structural and biochemical insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

RAS pathway mutations in juvenile myelomonocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Yeast two-hybrid in vivo association of the Src kinase Lyn with the proto-oncogene product Cbl but not with the p85 subunit of PI 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

The Src family kinase Fgr is critical for activation of mast cells and IgE-mediated anaphylaxis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Novel regimen for the treatment of juvenile myelomonocytic leukemia (JMML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Cbl: many adaptations to regulate protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-kappaB and induction of bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Targeting RAS signaling pathways in juvenile myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Molecular basis of juvenile myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Myelodysplastic and myeloproliferative disorders in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

A versatile lentiviral expression system to identify mammalian protein-protein interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

A Pilot Study of Isotretinoin in the Treatment of Juvenile Chronic Myelogenous Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.596

Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group

31 March 2020

1 reference

12 December 2020

Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors

1 reference

12 December 2020

Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia

1 reference

12 December 2020

The protein product of the proto-oncogene c-cbl forms a complex with phosphatidylinositol 3-kinase p85 and CD19 in anti-IgM-stimulated human B-lymphoma cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/ONC.2013.596

1 reference

8 September 2017

1 reference